Skip to main content
Premium Trial:

Request an Annual Quote

EndoChoice to Promote Exagen Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Exagen Diagnostics said today that it has signed up EndoChoice to promote its genomic tests for bowel disorders to gastrointestinal doctors in the US.

EndoChoice, which specializes in gastroenterology, will market Exagen's gene expression tests for diagnosing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Albuquerque, NM-based Exagen said in a statement.

Exagen CEO Scott Glenn said that the firm's eXaIBD and eXaIBS tests are sensitive and accurate at distinguishing IBD and IBS from other diseases

Exagen developed these tests using its Coperna computational tool and search engine, which identified genetic signatures associated with IBD and IBS.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.